Genesis IBRC India Peer Comparison

BSE: 514336

₹46.09

₹2.19 (4.99%)

As on 25-Sep-2026IST

Market cap

₹209 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

5.2

Div. Yield

0 %

Edit

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Market cap (₹ Cr)	209	2,681	160	49,272	40,205
Revenue (₹ Cr)	--	419	71	2,002	4,683
Net Profit (₹ Cr)	-0.86	79.66	5.14	575.95	552.34
Net Margin (%)	-2,391.67	18.53	7.16	26.66	11.55
RoE (%)	-3.56	18.52	5.85	20.48	14.93
Price to Earnings	--	33.66	45.94	85.55	72.29
Price-To-Book	5.24	5.70	2.19	15.74	9.78

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Operating Revenue	--	343.98	46.84	1,844.55	3,692.35
Total Income	3.67	348.22	47.52	1,930.29	3,797.15
Total Expenditure	0.16	222.03	39.30	1,173.52	2,831.90
EBITDA	-0.16	121.95	7.55	671.03	860.44
Depreciation	--	35.29	6.25	89.37	193.75
EBIT	-0.16	86.66	1.29	581.66	666.69
Interest	0.00	1.90	1.92	10.53	74.35
Other Income	3.67	4.24	0.68	85.73	104.81
Exceptional Items	--	--	--	--	-49.90
Profit before Tax	3.50	89.00	0.05	656.87	647.26
Provision for Tax	--	22.25	-0.01	205.61	165.94
Profit after Tax	3.50	66.76	0.06	451.26	481.32

Liabilities (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Shareholder's Funds	8.53	378.85	49.94	2,409.87	3,386.41
Minority Interest	--	--	0.13	--	1.10
Non-Current Liabilities	--	17.16	15.23	53.54	726.88
Current Liabilities	0.30	64.37	12.07	485.23	618.82
Total Liabilities	8.84	466.53	78.29	2,966.58	4,766.23

Assets (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Non-Current Assets	--	272.56	48.61	1,301.47	3,200.08
Current Assets	8.84	187.82	28.76	1,647.17	1,533.12
Total Assets	8.84	466.53	78.29	2,966.58	4,766.23
Total Debt*	0.00	8.52	15.14	108.96	327.88
Net Current Assets	8.53	123.45	16.69	1,161.94	914.31
Contingent Liabilities	--	2.74	--	54.44	88.77

Cashflow (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Cash From Operating Activities	0.00	94.05	10.07	270.55	623.76
Cash Flow from Investing Activities	--	-75.54	-15.62	-146.56	-720.94
Cash from Financing Activities	--	-16.12	5.24	-135.65	-97.23
Net Cash Inflow / Outflow	0.00	2.40	-0.30	-11.66	-194.41

Ratios

Profitability Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
ROCE (%)	51.69	25.23	3.17	28.55	20.50
ROE (%)	51.69	19.65	0.14	20.99	15.31
ROA (%)	49.91	15.76	0.08	16.64	10.72
EBIT Margin (%)	--	36.68	17.55	41.03	26.14
Net Margin (%)	95.57	19.17	0.12	23.38	12.68
Cash Profit Margin (%)	--	29.67	13.47	29.21	18.28

Growth Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Revenue Growth (%)	--	19.19	18.14	29.96	12.74
EBIT Growth (%)	192.30	29.09	53.88	33.05	9.24
Net Profit Growth (%)	192.29	36.76	104.45	22.86	0.68
EPS Growth (%)	192.29	36.36	109.10	22.85	0.65
Book Value Growth (%)	69.71	21.06	1.09	23.43	16.71

Valuation Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Price / Earnings	6.80	16.66	526.25	0.00	66.85
Price / Book Value	2.79	5.98	1.45	0.00	9.50
Dividend Yield (%)	0.00	0.20	0.00	--	0.04
EV/EBITDA	6.80	17.43	9.54	0.06	32.52
Market Cap (₹ Cr)	--	2,223.71	63.50	0.00	32,181.74

Solvency Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Debt to Equity	0.00	0.02	0.34	0.05	0.10
Short term debt to equity ratio	--	0.02	0.02	0.02	--
Current Ratio	29.18	2.92	2.38	3.39	2.48
Quick Ratio	29.18	2.53	2.25	2.69	2.37
Interest Coverage	0.00	47.84	1.03	63.40	9.71

Operating Efficiency Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Debtors to sales (%)	--	30.89	34.03	24.42	7.90
Asset Turnover	0.00	0.81	0.65	0.68	0.82
Receivable days	--	102.52	110.00	92.78	25.07
Inventory Days	--	26.39	10.55	54.41	6.62
Payable days	--	0.00	255.53	51.72	79.17
Cash Conversion Cycle	--	122.88	-134.98	95.47	-47.48

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.